Duchenne Community Punched Again: Akashi Suspends Trial
This article was originally published in Scrip
The Duchenne muscular dystrophy (DMD) community was hit in the gut for the third time in the past few weeks with another setback in the development of a drug to treat the rare severely debilitating and fatal neuromuscular disease when Akashi Therapeutics Inc. disclosed it had suspended its HALO trial of its experimental therapy HT-100 after one patient receiving the highest dose experienced serious, life-threatening health issues.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.